Address
171 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
650 489 9000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
42
First IPO Date
January 11, 2021
| Name | Title | Pay | Year Born |
| Craig C. Parker | Chief Executive Officer, President & Director | 976,500 | 1962 |
| Yang Li | Executive Vice President of Research | 642,100 | 1969 |
| Charles Williams | Chief Operating Officer & Corporate Secretary | 689,786 | 1980 |
| Roeland Nusse | Co-Founder & Member of Scientific Advisory Board | 0 | 1950 |
| Esther Jhun | Controller | 0 | N/A |
| Calvin Kuo | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Daniel L. Chao | Vice President and Head of Clinical Development | 0 | N/A |
| Andrew Maleki | Chief Financial Officer | 0 | 1990 |
| Michael Lauw | Senior Vice President of Development Operations | 0 | N/A |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.